Hong Kong registry for diabetes-related fatty liver disease
The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
This project will see how common and how severe fatty liver is among adults with type 2 diabetes in Hong Kong.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, New Territories) |
| Trial ID | NCT07437157 on ClinicalTrials.gov |
What this trial studies
This observational registry enrolls adults with type 2 diabetes at the Chinese University of Hong Kong / Prince of Wales Hospital to systematically record liver health and metabolic data. Participants will undergo noninvasive liver tests such as controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), alongside routine blood tests and clinical history. The registry is designed to quantify the prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with T2DM and to identify clinical factors linked with advanced fibrosis. No experimental treatments are given; the data will support epidemiologic analyses and guide future clinical research.
Who should consider this trial
Good fit: Adults aged 18 or older with type 2 diabetes who can give written informed consent are the intended participants.
Not a fit: People with type 1 diabetes, those with terminal illness, or anyone judged ineligible by the investigators are not candidates and may not benefit from this registry.
Why it matters
Potential benefit: If successful, the registry could help identify people with diabetes who have undiagnosed fatty liver or advanced fibrosis so they can receive earlier monitoring or treatment.
How similar studies have performed: Previous observational studies and registries have reported high rates of hepatic steatosis and some advanced fibrosis in people with T2DM, supporting the value of this data-collection approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * T2DM. * Aged ≥ 18 years. * Able and willing to give Informed written consent. Exclusion Criteria: * Type 1 diabetes. * Terminal illness such as malignancy with limited life expectancy. * Any condition, as judged by the investigators, as ineligible to participate in this study.
Where this trial is running
Hong Kong, New Territories
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital — Hong Kong, New Territories, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Alice Pik Shan Kong, MD
- Email: alicekong@cuhk.edu.hk
- Phone: +852 3505 2648
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.